In parallel to the uncontrolled use of antibiotics, the emergence of multidrug-resistant bacteria, like *Acinetobacter baumannii*, has posed a severe threat. *A. baumannii* predominates in the nosocomial setting due to its ability to persist in hospitals and survive antibiotic treatment, thereby eventually leading to an increasing prevalence and mortality due to its infection. With the increasing spectra of drug resistance and the incessant collapse of newly discovered antibiotics, new therapeutic countermeasures have been in high demand. Hence, recent research has shown favouritism towards the long-term solution of designing vaccines. Therefore, being a realistic alternative strategy to combat this pathogen, anti-*A. Baumannii* vaccines research has continued unearthing various antigens with variable results over the last decade. Again, other approaches, including pan-genomics, subtractive proteomics, and reverse vaccination strategies, have shown promise for identifying promiscuous core vaccine candidates that resulted in chimeric vaccine constructs. In addition, the integration of basic knowledge of the pathobiology of this drug-resistant bacteria has also facilitated the development of effective multiantigen vaccines. As opposed to the conventional trial-and-error approach, incorporating the *in silico* methods in recent studies, particularly network analysis, has manifested a great promise in unearthing various antigens with variable results over the last decade. Again, other approaches, including pan-genomics, subtractive proteomics, and reverse vaccination strategies, have shown promise for identifying promiscuous core vaccine candidates that resulted in chimeric vaccine constructs. In addition, the integration of basic knowledge of the pathobiology of this drug-resistant bacteria has also facilitated the development of effective multiantigen vaccines. As opposed to the conventional trial-and-error approach, incorporating the *in silico* methods in recent studies, particularly network analysis, has manifested a great promise in unearthing novel vaccine candidates from the *A. baumannii* proteome. Some studies have used multiple *A. baumannii* data sources to build the co-functional networks and analyze them by k-shell decomposition. Additionally, Whole Genomic Protein Interactome (GPIN) analysis has utilized a rational approach for identifying essential proteins and presenting them as vaccines effective enough to combat the deadly pathogenic threats posed by *A. baumannii*. Others have identified multiple immune nodes using network-based centrality measurements for synergistic antigen combinations for different vaccination strategies. Protein-protein interactions have also been inferred utilizing structural approaches, such as molecular docking and molecular dynamics simulation. Similar workflows and technologies were employed to unveil novel
A. baumannii drug targets, with a similar trend in the increasing influx of in silico techniques. This review integrates the latest knowledge on the development of A. baumannii vaccines while highlighting the in silico methods as the future of such exploratory research. In parallel, we also briefly summarize recent advancements in A. baumannii drug target research.

Keywords: Acinetobacter baumannii, vaccine candidate, chimeric vaccine, ghost vaccine, drug target, in silico methods, bioinformatics, interactome analysis

INTRODUCTION

As one of the dreadful ESKAPE pathogens, A. baumannii has become a worldwide threat due to its resistance to a broad spectrum of currently available drugs, especially in the nosocomial setting (1). This is evident from the enormous mortalities of immunocompromised cases (2, 3) by this opportunistic pathogen. For example, a systematic statistical meta-analysis published in The Lancet reported A. baumannii as one of the six leading pathogens causing mortalities due to drug resistance, of which carbapenem-resistant A. baumannii has caused at least 50,000 deaths globally in the year 2019 (4). Moreover, the healthcare crisis caused by A. baumannii, especially the carbapenem-resistant strains, has peaked in intensive care units (ICU) synchronously with the COVID-19 pandemic (5, 6). Therefore, in parallel to the relentless drug resistance acquisition in A. baumannii towards currently available antibacterial drugs, biomedical research in discovering novel vaccines and drug targets remains exigent (7, 8).

Novel vaccine and drug development often require decades or even centuries (9, 10). Reportedly, there are no vaccine candidates for A. baumannii that have stepped into clinical trials (11–14). For vaccine candidates to step into clinical studies, assessing their in vivo reactogenicity and immunogenicity in animal models becomes mandatory (15). In addition, the pharmacological and toxicological properties of the targeted vaccine candidates are investigated along with the preclinical studies. Additionally, drug target selection, serving as the first and the most crucial step into drug development, is always supported by prior knowledge and robust characterisation of the proteins of interest or their related biological pathways from the scientific literature (16). The preliminary tests of a drug target’s viability include knockout and expression studies of the targeted gene under stress, both for in vivo and in vitro models (16, 17).

In the light of the rapid development in multi-omic methods, as well as databases curated thereof, the contribution of bioinformatics based studies has been ubiquitous in research efforts on combating multidrug-resistant bacteria (18–21). For instance, by analysing the bacterial genome or proteome via in silico approaches such as protein interactome analysis, one can unveil novel crucial proteins in the bacteria of interest, which can potentially be vaccine candidates (22–24). With the increasing entries in experimentally validated 3D structure database, PDB, the strength of interactions between small molecules and proteins, as well as protein-protein interactions, can now be predicted via in silico approaches (25–27). Such a technique has also been employed in vaccine research by computationally inferring peptide-binding onto immune cell receptors (28). Almost similar methods are seen in the in silico drug target research. For example, virtual screening of large chemical databases on drug-target of interest can unearth novel antibacterial drugs to be repurposed or further developed (29, 30).

Exploring novel vaccine candidates or streamlining antigenic peptide regions through experimental screening on animal models is tremendously cost and time expensive; therefore, bioinformatics tools in aiding in silico vaccine design have been numerous and extensive (31, 32). Linear B- and T-cell epitope prediction tools, such as EpiJen, MHCPred, and NetMHC, have been prevalent and well-recognised as upstream exploratory research in vaccine design (33–35). Moreover, researchers have also developed bioinformatic tools to predict the allergenicity and toxicity of vaccine candidates, such as AllergenFP and ToxinPred, respectively (36, 37).

Over the years, bacteria have gained resistance to the newly developed drugs at a breakneck speed. Consequently, recent exploration favours escalating vaccine research rather than unveiling novel drug targets (38). This review summarizes the recent advancements in A. baumannii vaccine design (Figure 1). In concordance with the recent studies’ heavy use of computational methods, we accentuate bioinformatics as the future of exploratory research in shepherding drug target selection and vaccine candidature and the multitudinous influx of novel insights into its implication. Moreover, we also briefly discuss A. baumannii drug target research, which acts as a temporary coping while we wait for the new vaccines to arrive.

INFERRING NOVEL VACCINE CANDIDATES FROM LABORATORY MEANS

Conventional means of inferring novel vaccine candidates require prior established knowledge of the proteins or metabolic pathways of interest and often involve in-depth characterisation of the potential proteins of interest. In addition, deducing new vaccine candidates via laboratory means often involves animal models; thus, initial molecular characterisation is almost necessary (39).
Advancements in Vaccines Derived From Whole-Cell or Anatomical Components

Live vaccines are the most immunologically representative units in establishing vaccination despite posing a danger in regaining infectivity (40). Sequential intraperitoneal immunisation, with sub-lethal doses of different *A. baumannii* strains, has elicited antibody responses towards antigens of multiple strains in CD1 mice (41). Furthermore, a study on virulence switch in *A. baumannii* has highlighted the overexpression of a TetR-type transcriptional regulator, *ABUW_1645*, that facilitated the transformation of the cellular stage from virulent opaque (VIR-O) to avirulent translucent (AV-T) while proposing the potential of *ABUW_1645*-overexpressing *A. baumannii* to be utilized as a live-attenuated vaccine (42).

Bacterial outer membrane vesicle (OMV) has been an attractive vaccine candidate as it contains the outer membrane proteins (43). As lipopolysaccharide (LPS) is abundant in OMV, a study on the efficacy of OMV vaccine on LPS-deficit *A. baumannii* has disproved the effect of LPS on OMV production through electron microscopy (44, 45). In addition, the study also reported similar immunisation strength between OMV isolated from wild-type and purified LPS supplemented LPS-deficit *A. baumannii* by conferring complete protection to the C57BL/6 mouse model (44).

Bacterial outer membrane vesicle (OMV) has been an attractive vaccine candidate as it contains the outer membrane proteins (43). As lipopolysaccharide (LPS) is abundant in OMV, a study on the efficacy of OMV vaccine on LPS-deficit *A. baumannii* has disproved the effect of LPS on OMV production through electron microscopy (44, 45). In addition, the study also reported similar immunisation strength between OMV isolated from wild-type and purified LPS supplemented LPS-deficit *A. baumannii* by conferring complete protection to the C57BL/6 mouse model (44).

Like inactivated vaccines, bacterial ghosts are gram-negative bacteria depleted of their cytoplasmic and genetic constituents through E-mediated lysis, leaving only the cell envelopes (46). A study on the effectiveness of *A. baumannii* ghosts in conferring vaccinated protections in Sprague-Dawley rats has suggested promising results in terms of effectiveness and safety on various administration methods, including subcutaneous, intramuscular, and intraperitoneal injections (47).

The replicative ability of bacteria can be disabled through the depletion of nucleic acids via gamma radiation exposure, with the protection by a specific antioxidant cocktail, and hence eventuating whole-cell inactivated vaccine with better immunogenicity than chemically inactivated vaccines (48–50). Studies showed that intranasal administration of radiation-inactivated *A. baumannii* grown via either planktonic cultures in rich media or biofilm cultures in static cultures underneath M9 media had conferred good protection in both healthy and neutropenic mouse models (51).

Novel Breakthroughs in Subunit Vaccine Research

Due to their safety and stable nature in various conditions, subunit vaccines have been ubiquitous in vaccine design studies (52, 53). Due to the crucial role of Omp34 in enhancing *A. baumannii* virulence and fitness, the Omp34 subunit vaccine has been proposed and reported to be protective in the BALB/c mouse model (54). The 263 amino acid long C-terminal end of an essential *A. baumannii* virulence factor, Ata (rcAta 263), has elicited immune protection via subcutaneous, intraperitoneal, and intranasal challenge in the BALB/c mouse model (55). The combination of two recombinant pilus proteins, namely CsuA/B and FimA, administered via subcutaneous injection, has been reported to confer partial (62%) protection in the BALB/c mouse model (56). The subcutaneous co-immunisation of two outer membrane serum resistance factors, CipA and PBP-7/8, has also conferred...
80% protection in the C57BL/6 mouse model from the lethal dose *A. baumannii* challenge (39). Moreover, intramuscular injection and passive immunisation of a 711-aa long C-terminal fragment of *A. baumannii* Blp1 protein have protected the lethal challenge in the BALB/c mouse model (57).

As a crucial component on bacterial surfaces, polysaccharides serve as attractive targets for vaccine design. As polysaccharides alone do not elicit an adequate immune response, the conjugation of carrier proteins is often required (58). Upon misuse of antibiotics, *A. baumannii* can produce capsular polysaccharides (CPS) to enhance antibiotic resistance and virulence (59). By introducing the O-glycosylation system from Neisseria into *A. baumannii*, a resulting in vivo produced bioconjugated vaccine, having *A. baumannii* CPS and recombinant cholea toxin B subunit (CTB<sup>4573C</sup>) and aluminium hydroxide adjuvant, was reported to manifest good protection and safety in the BALB/c mouse model (60).

By injecting DNA coding for immunogenic antigens into the host *via* a plasmid, immune protection from vaccination can be expected through antigenic expression by host cells (61). Intramuscular injection of DNA vaccine encoding *A. baumannii* OmpA and Pal, adjuvanted by CpG oligodeoxynucleotides (CpG ODN), into C57BL/6 mice exhibited immunological protection against clinical strains of *A. baumannii*, driven by adaptive immune response activation (62). Another study has also designed and proposed the *A. baumannii* OmpA-derived DNA vaccine, pBudCE4.1-ompA, as protective against lethal-dose challenge in the BALB/c mouse model (63, 64). Intramuscular injection of nlpA DNA vaccine into BALB/c mouse model has also successfully elicited an immune response in a study by Hashemzehi et al. (65). With the recently claimed success of the mRNA vaccine in controlling the coronavirus disease 2019 (COVID-19) pandemic, one can explore the feasibility of the *A. baumannii* mRNA vaccine in the future (66).

Due to the high conservation of specific essential genes across different bacterial species, cross-reactivity of subunit vaccines derived from these genetic sections occurs. For example, a study utilizing the Swiss albino mouse model showed the feasibility of *P. aeruginosa* N-terminal OprF (OprF<sub>53-200</sub>) adjuvanted with Bacillus Calmette-Guerin (BCG) and aluminium hydroxide in conferring cross-reactive immunisation to both *P. aeruginosa* and *A. baumannii* (67). Another study proposed recombinant *A. baumannii* BamA (rAbBamA) protein as a potential vaccine candidate *via* intramuscular challenge on C57/BL6 mouse model adjuvanted by aluminium hydroxide, while reported potential cross-reactivity across *K. pneumoniae* and *E. coli* *via* immunoblot assay of anti-rAbBamA (68).

**IN-SILICO METHODS IN DRIVING EXPLORATORY RESEARCH ON NOVEL VACCINES**

With the rapid advancement of bioinformatics in extracting and predicting multi-omic information, as well as the expansion of proteomic and genomic databases, research attempts in unearthing vital proteins as novel vaccine candidates have become more expensive and increasingly prevalent (69–71). By mapping small protein interactomes (SPIN) of virulent factors, vaccine candidates, and key factors retrieved from literature onto the whole genome protein interactome (GPIN), a study has reported crucial proteins *via* co-functional network analysis and k-shell decomposition, which can serve as potential vaccine candidates (22). Besides, a theoretical study on hypothetical proteins (HPs) in 30 multidrug-resistant *A. baumannii* strains has proposed 4 HPs as potential vaccine candidates *via* in *sili*co immunological analyses (72). In addition, utilizing *in silico* functional analysis, the authors also proposed the druggability of 7 HPs. Upstream subtractive proteomics, combined with linear T and B cell epitopes prediction, structural screening with immune cell receptors, and druggability analysis, have finalised a chimeric subunit vaccine candidate derived from TolC and MrCB in *A. baumannii*, as well as 13 potentially druggable proteins (73).

**Immunoinformatics and Proteomics in Vaccine Design**

Bioinformatics approaches, especially proteomics, have been extensively applied in recent studies by ushering the mining of core protein candidates in downstream vaccine design and modifications (Figure 2). For instance, applying pan genomics in inferring gene conservation across species or strains (74), predicting immunogenicity in proteins and inferring epitopes through reverse vaccinology (75), and inferring essential proteins involved during infection *via* proteomic interactomes (76, 77). Furthermore, predicting effective T and B-cell epitopes has been an essential step during vaccine design in ensuring that only the specific immunogenic parts of the candidate proteins are retained *via* peptide truncation due to cost and time efficiency in laboratory or downstream bulk production (78).

A study has applied reverse vaccinology to 33 genomes of *A. baumannii* strains, and downstream B-cell epitope analysis has indicated the potential of two outer membrane proteins, sllcietc a DcaP-like protein and HP-2, a novel hypothetical protein, as vaccine candidates (79). Moreover, Beiranvand et al. has integrated the predicted protein and epitope topology on the bacterial membrane surface to the usual vaccine design workflow, namely B cell epitope, subcellular, antigenicity, and solubility predictions, and finalised with CarO, OmpH, LptE, FimF, and PfsR as top five *A. baumannii* vaccine candidates (80, 81). Furthermore, linear prediction of epitopes and their properties has also been conducted on GacS, a virulence modulator *via* citrate metabolism pathway, resulting in five peptides being proposed as *A. baumannii* vaccine candidates (82).

Genomic and proteomic sequence analyses have been employed to search for the conserved sequence to serve as vaccine candidates. Following transcriptional characterisation of *A. baumannii* Omp33-36 protein to highlight its role during the initial phase of infection, phylogenetic analyses have revealed an 8-aa highly conserved motif (PLAEAAFL), potential enough for vaccine development processing (83). Moreover, comparative genomics on *A. baumannii* OmpA of different strains, with downstream *in silico*
prediction of T and B cell epitopes, as well as in silico characterisation and molecular docking with TLR-2, has derived a 25 amino acids long vaccine candidate by Sogasu et al. (84). Furthermore, another study has demonstrated the integration of pan genomic analysis of around 4200 genomes, T and B cell epitope predictions, and network-based centrality methods in identifying multiple immunologic nodes in A. baumannii, which can result in the elucidation of combinatorial synergy in different antigens for different vaccination strategies (85).

In addition to linear prediction of T and B cell epitopes, structure-based downstream analysis, such as structure modelling, molecular docking, and molecular dynamics (MD) simulation, has been integrated to confer more robust computational insights. For example, utilizing T and B cell epitope prediction, immunological feature screening, molecular docking with immune cell receptors, and downstream integration of in silico gene cloning, a multi-epitope vaccine design has been proposed computationally from A. baumannii CarO, an outer membrane protein associated with carbapenem resistance (86). Again, utilizing a similar approach, Khalid et al. has also proposed an in silico designed vaccine derived from A. baumannii DcaP protein (87).

More comprehensive in silico approaches have also been conducted in vaccine design. For instance, upstream integration of pan genomics, subtractive proteomics, and reverse vaccinology into T and B cell epitope prediction, pipelined with downstream in silico immunological simulation and structure-based screening onto immune cell receptors, two A. baumannii multi-epitope vaccine constructs with good safety profiles have been designed (88). Another study on Tigecycline-resistant A. baumannii utilized subtractive proteomics, exoproteome and secretome predictions, interactome analysis, as well as other physicochemical and immunological predictions to propose a chimeric vaccine design. The vaccine’s predicted T and B cell epitopes are from three proteins, scilicet BamA, an outer membrane protein assembly complex, FimD, an outer membrane usher protein, and Rhs, a type IV secretion protein (89). An integrated approach of extracting A. baumannii virulent factors from the VFDB database, secretome and exoproteome analysis, subtractive proteomics, B and T cell epitope prediction, as well as peptide docking analysis, has resulted in two nine amino acid long potential vaccine candidates derived from EpsA and CsuB, respectively (90).

To facilitate ex silico robustness of computationally predicted results, downstream in vitro and in vivo models have been utilized. For example, predicted T and B cell epitopes of an A. baumannii outer membrane protein, TolB, were verified to be antigenic in vivo, by utilizing lymphocyte proliferation assay and

---

**FIGURE 2** A typical workflow of in silico vaccine design in recent studies on A. baumannii.
ELISA, respectively, in a mouse model (91). In another study on the feasibility of vaccine design based on VgrG, a type VI secretion system (T6SS) component, the immunisation of two peptides derived from A. baumannii VgrG conserved sequences (vgrG_{1159-2196} and vgrG_{1159-1502}) in BALB/c mice has conferred protection from lethal-dose challenges (92). Again, ABAYE2132, an A. baumannii fimbrial protein previously proposed via reverse vaccinology, has been translated into an animal study, and its protection capability towards subcutaneously injected BALB/c mouse model was conferred via lethal-dose challenge (93). Moreover, a study has proposed a novel synthetic peptide derived from A. baumannii OmpA protein using the overlapping regions of predicted T and B cell epitopes, pipelined with three-dose subcutaneous injection in C5BL/6 SPF mouse model, which eventually observed spiked antibody production in the injected mice (94). Another study on the A. baumannii OmpA protein has proposed a 27 amino acid long peptide as a vaccine candidate by manifesting protection towards the challenge in C5BL/6 mice (95). Moreover, a recombinant multi-epitope protein has been designed from predicted T and B cell epitopes of A. baumannii outer membrane proteins, namely FilF and NucAb, which conferred immunogenicity and protection in the BALB/c mouse model (96). Similar approaches have been adopted by Raoufi et al. on DcaP, a porin protein in A. baumannii, which has manifested protection against the challenge in BALB/c mice (97). Furthermore, Abdollahi et al. named a previously hypothetical protein in A. baumannii, PcTPRS1, and derived a 101 amino acid long subunit vaccine based on its in-silico predicted T and B cell epitopes, subcellular locations, physiochemical properties, as well as in vivo challenge on BALB/c mouse model supplemented by Freund’s adjuvant via subcutaneous injection (98). Recently, the A. baumannii recombinant multi-epitope Omp22 vaccine derived from its predicted T and B cell epitopes, with chitosan and poly lactic-co-glycolic acid (CS-PLGA) nanoparticles encapsulation, has been proposed as a potential nanovaccine candidate with reported protection towards lethal intratracheal challenge on BALB/c mice (99).

**In Silico Methodologies to Nominate Vaccine Candidates**

With the surfacing of more sophisticated bioinformatics tools over the recent years, in silico approaches in unveiling potential vaccine candidates within the A. baumannii proteome have become highly diverse. However, it can be stratified into two major categories: the upstream and the downstream analysis. The upstream analysis of vaccine candidature aims to mine a subset of potential candidates from a vast pool of proteins, usually the whole proteome, genome, and pan-genome. Furthermore, the downstream analysis aims either to shape the protein candidates into effective epitopes or to validate the feasibility of the proposed vaccine candidates, albeit computationally.

The upstream analysis of in silico vaccine candidature includes protein interactome analysis, which rationally helps to unearth the protein central to the interactome and thus, plays a crucial role in the pathogenesis/pathophysiology of the disease (22). Therein, the connectivity between each protein can be extracted from the protein interaction metadata database like STRING (100), while network visualisation software tools and plugins like Cytoscape (101), CytoNCA (102), and NetworkAnalyzer (103) help in the analysis. Other analyses, such as k-core analysis, can be conducted externally using MATLAB (104). The pan-genome analysis allows the analysis of inter-species or -strain gene conservation, thus eventuating vaccine candidates with a broad spectrum of targets and high tolerance towards mutation. Such analysis can be done via the Bacterial Pan Genome Analysis Tool (BPGA) (105) and PanRV pipeline (106). Subtractive proteomics inspects the homology of the target proteome of interest with the host proteome, for example, the A. baumannii proteome and human proteome, to avoid integration into the host genome. This can be achieved using the BLASTp tool accelerated with in-house scripts (90). Predictions on the properties of the proteins of interest, such as subcellular localisation of proteins and signal peptides, can be vital in reverse vaccinology. Protein subcellular localisation can be predicted via PSORTb (107), CELLO (108), PSLpred (109), and Gneg-mPLoc (110), while the signal peptides localisation can be predicted via SignalP (111).

One significant component of the downstream analysis is T and B cell epitope prediction; such bioinformatic tools include ABCPred (112), ProPred (113), as well as IEDB tools such as Discotope (114), EliiPro (115), and TepiTool (116). The predicted epitopes are sometimes backed up by external antigenicity prediction tools, such as Vaxign (117), ANTIGENpro (118), and Vaxijen (119). Safety profiles prediction, such as allergenicity of the predicted epitopes, can be conducted using AllergenFP (36) and AlgPred (120). Besides, ToxinPred (37) gives an idea of the related toxicity. Physiochemical properties such as molecular weight, stability, and hydropathicity, can be predicted using the Expasy ProtParam server (121). The binding capabilities of epitopes to immune cell receptors can also be predicted using the structural method. For instance, the 3D structure of the epitopes can be predicted using I-TASSER (122) and SWISS-MODEL (123). Peptide docking tools such as HADDOCK (124), FireDock (125), and PatchDock (126) can predict epitope binding strength onto immune cell receptors. Eventually, the epitope binding dynamics can be simulated through MD simulation method via GROMACS (127).

**RECENT RESEARCH ON VALIDATING NOVEL DRUG TARGETS**

Aside from all the hype on vaccine research, efforts in foraging novel drug targets remain inevitable and in tremendous demand prior to the approval, introduction, and global distribution of new vaccines into the human population.

**Unearthing Drug Targets Using Conventional Means**

Like vaccine research, unveiling novel drug targets via conventional laboratory approaches requires extensive
molecular knowledge or characterisation of the protein of interest or its biological pathway. Most frequently employed approaches in inferring drug targets include knockout study and chemical inactivation of protein function to inspect its essentiality in ensuring bacterial survival (128, 129).

Instead of exploring novel direct bactericidal drug targets, recent research has sought adjuvant therapy drug targets in the molecular components that contribute to bacterial virulence and drug resistance. For instance, colistin, or polymyxin E, has been a prominent final resort for severe A. baumannii infection, and its resistance is mediated by the pmrCAB operon, which codes for phosphoethanolamine (PteN) and two-component system (TCS), as well as PetN addition to the LPS lipid A (130). Moreover, a knockout study on colistin resistance has suggested PetN transferases, scilicet PmrC and EptA, as promising drug targets in attenuating colistin resistance in A. baumannii while disproving PmrA, a transcriptional regulator mediating PmrC overexpression, as a drug target due to its limited spectrum (131). Furthermore, utilizing a chemical scaffold compound that inhibits the enzymatic activity of FabI, FabI has manifested druggability in A. baumannii by enhancing the bactericidal effect of colistin (129).

Aside from attenuating drug resistance, attempts to promote bacterial susceptibility to the immune system have been observed in research studies. Notably, copper, has been an interesting antibacterial molecule employed by the immune system to facilitate pathogenic clearance upon infection, manifested by a copper burst in macrophage phagosomes and blood (132–134). In this regard, Williams et al. has reported 11 proteins that result in A. baumannii sensitivity to copper upon loss-of-function mutations, with two of them, scilicet CusR and CopD, being validated in the BALB/c mouse model in causing less mortality (135). These proteins rendering copper resistance could serve as potential drug targets in weakening A. baumannii virulence. Again, another study has proposed the druggability of OxyR, a transcriptional regulator in hydrogen peroxide detoxification, via a knockout study (128). Additionally, through in vivo imaging, the authors have supplemented the finding that A. baumannii in the lungs suffers oxidative stress from hydrogen peroxide.

**In-Silico Methods in Mining Novel Drug Targets**

With the enormous growth in the variety and size of biological databases, different databases have been innovatively extracted in inferring drug targets. Potentially bactericidal drug targets burrowed in vast and complex datasets could be unearthed with comprehensive analyses on annotated multi-omic sequences (Figure 3) (136). For example, in synchronous to the increasing attention towards the TCS in bacteria, pan-genomics and sequence variation analysis on TCS proteins in seven pathogen species, inclusive of A. baumannii, has been conducted by Rajput et al., who have reported BaeSR, KdpDE, Evg8A, RstBA, DcuSR, and TorSR as potentially druggable targets (137). Moreover, the Toxin-Antitoxin database (TADB) pipelined with comparative genomics and phylogenetic analysis, as well as in vitro transcriptional analysis upon oxidative and antibiotic stress, has demonstrated the potential druggability of A. baumannii CptBA Toxin-Antitoxin system in disrupting intracellular toxin-antitoxin balance, hence eventuating cell suicide (17). Furthermore, integrated analysis of metabolic pathways and chokepoints via the KEGG database (138), plasmid proteins, virulence factors via the VFDB database (139), and drug resistance proteins via the CARD database (140), pipelined with subtractive analysis of essentiality and non-homology, Kaur et al. have presented 58 potentially druggable proteins of which eighteen (18) existed or had their homologs in DrugBank (141, 142). Additionally, utilizing KEGG pathway analysis, essentiality analysis from the DEG database (143), and subtractive proteomics, Uddin et al. have presented eighty-six (86) potentially druggable proteins, with forty-five (45) exhibiting high sequence similarity with the existing drug targets in DrugBank (144).

Besides the above, bioinformatics approaches downstream of drug target identification often include virtual screening via molecular docking and MD simulation, and hence, experimentally crystallised protein 3D structures have become a godsend in recent research (29, 30, 145). In this regard, in a study, researchers have crystallised the 3D structures of 29 essential proteins in A. baumannii and deposited them in Protein Data Bank (PDB), fifteen (15) of which were recommended to be druggable, based on active site features and sequence homology (146).

**OTHER PROTEOMICS-DRIVEN STRATEGIES**

Aside from the unveiling of novel vaccines and drug targets, recent proteomics research on other strategies such as antimicrobial peptides (AMPs) have been promising in combating A. baumannii (147). In a study by Jung et al., in vivo screening of AMPs in a mouse model has reported SMAP-29 and TP4 to exhibit prophylactic properties, while dC4 and dN4 exhibited potential therapeutic activity against A. baumannii (148). Moreover, a hexahistidine-tagged AMP, namely Lys AB2 P3-His, with a gold nanoparticle carrier, AuNP-Apt, has conferred significant protection to mice against lethal-dose A. baumannii challenge (149). Other than direct antimicrobial activities, the additional capabilities of AMPs in enhancing drug effects have been explored. Esc(1-21), a frog-skin AMP derivative, has manifested synergistic membrane-perturbing antibacterial activity with colistin on multidrug-resistant A. baumannii clinical isolates (150). In silico study on AMPs has been prevalent with the increasing availability of peptide-peptide docking. A virtual screening study by He et al. with a set of cyclic peptides against A. baumannii BamA, pipelined with downstream in vivo mouse model challenge, has proposed cyclo-RRWWRRW to be membrane-perturbing bactericidal (151). Another study has demonstrated the in silico screening of human proteome for encrypted AMPs to be translatable into in vivo mouse models (152).
CONCLUSION

The increased utilization of bioinformatic approaches in exploring *A. baumannii* vaccines has invited a tremendous influx of passion and novel research outputs in combating the notorious nosocomial pathogen, mainly due to its immense cost and time efficiency. We can unveil potential vaccine candidates by extracting and collating information through different databases with statistical means. In addition to employing bioinformatics tools with straightforward outputs, supplementary approaches, such as comparative genomics, subtractive proteomics, and interactome analyses, have been conducted to strengthen or further streamline the shortlisted vaccine candidates. Similar research trends and methodologies can be observed in unveiling novel drug targets. In the light of the rapid expansion of drug resistance spectra in bacteria, scouring for novel vaccine candidates seemed to be a more attractive choice than tramping in the vicious cycle of bacteria rapidly acquiring drug resistance. Nonetheless, due to the long timeline of vaccine research, unearthing novel drug targets remains crucial while waiting for new vaccines to be developed and distributed. As research progresses, bioinformatics databases and methodologies will continue to confer valuable insights in pushing through the vaccine research to combat the *A. baumannii* infection.

AUTHOR CONTRIBUTIONS

YT primarily wrote the manuscript aided by complete editorial up-gradation by CL. In addition, figures were generated by YT with guidance provided by CL. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGEMENTS

The authors thank Shrikant Pawar for providing some thoughts upon the project initiation.

REFERENCES

1. De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial Resistance in ESKAPE Pathogens. *Clin Microbiol Rev* (2020) 33(3):e00181-19. doi: 10.1128/CMR.00181-19
2. Nocera FP, Attigli A-R, De Martino L. *Acinetobacter baumannii*: Its Clinical Significance in Human and Veterinary Medicine. *Pathogens* (2021) 10(2):127. doi: 10.3390/pathogens10020127
3. Thompson T. The Staggering Death Toll of Drug-Resistant Bacteria. *Nature News*, [online]. p. 1. Available at: https://www.nature.com/articles/d41586-022-00228-x [Accessed 10 April 2022].
4. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Antimicrobial Resistance Collaborators. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. *Lancet* (2022) 399(10325):629–55. doi: 10.1016/S0140-6736(21)02724-0
5. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii Antibiotic Resistance Mechanisms. *Pathogens* (2021) 10(3):373. doi: 10.3390/pathogens10030373
6. Thoma R, Seneghini M, Seiffert SN, Vuichard Gysin D, Scanferla G, Haller S, et al. The Challenge of Preventing and Containing Outbreaks of Multidrug-Resistant Organisms and Candida Auris During the Coronavirus Disease 2019 Pandemic: Report of a Carbapenem-Resistant Acinetobacter baumannii Outbreak and a Systematic Review of the Literature. *Antimicrob Resist Infect Control* (2022) 11(1):12. doi: 10.1186/s13756-022-01052-8
7. Suranadi IW, Fatmawati NND, Aryabiantara IW, Sinardja CD, Saputra DJ, Senapathi TGA, et al. *Acinetobacter baumannii* is an Opportunistic Pathogen as an MDRO Especially on Intensive Ward. *Bali J Anesthesiol* (2019) 3(2):150–3. doi: 10.15562/bjoa.v3i2.199
8. Zhang T, Xu X, Xu C-F, Bilya SR, Xu W. Mechanical Ventilation-Associated Pneumonia Caused by *Acinetobacter baumannii* in Northeast China Region: Analysis of Genotype and Drug Resistance of Bacteria and Patients’ Clinical Features Over 7 Years. *Antimicrob Resist Infect Control* (2021) 10(1):135. doi: 10.1186/s13756-021-01005-7
9. Kim YC, Dema B, Reyes-Sandoval A. *COVID-19* Vaccines: Breaking Record Times to First-in-Human Trials. *NPJ Vaccines* (2020) 5(1):34. doi: 10.1038/s41541-020-0188-3

FIGURE 3 | Canonical workflow of unearthing novel drug targets in *A. baumannii* via *in silico* approaches.
Tan and Lahiri

Vaccine Candidates of Acinetobacter baumannii

48. Datta SK, Okamoto S, Hayashi T, Shin SS, Mihajlov I, Ferrn A, et al. Vaccination with Irradiated Listeria Induces Protective T Cell Immunity. PLoS Pathog (2020) 16(5):e1008532. doi: 10.1371/journal.ppat.1008532

49. Gaidamakova EK, Myles IA, McDaniel DP, Fowler CJ, Valdez PA, Naik S, et al. Preserving Immunogenicity of Lethally Irradiated Viral and Bacterial Vaccine Epitopes Using a Radio-Protective Mn2+-Peptide Complex from Deinococcus. Cell Host Microbe (2012) 12(1):17-24. doi: 10.1016/j.chom.2012.05.011

50. Gayen M, Gupta P, Morazzani EM, Gaidamakova EK, Knollmann-Ritschel B, Daly MJ, et al. Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alleviate the Immunosuppressive Effects of Alkylating Agents. Vaccine (2016) 35(29):3672-81. doi: 10.1016/j.vaccine.2017.05.016

51. Dollery SJ, Zarawski DV, Gaidamakova EK, Matrosova VY, Tobin JK, Wiggins TJ, et al. Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates. Vaccines (2021) 9(2), 96. doi: 10.3390/vaccines9020096

52. Baxter D. Active and Passive Immunity, Vaccine Types, Excipients and Licensing. Occup Med (2007) 57(8):552-6. doi: 10.1093/occmed/kqm109

53. Vartak A, Sucheck S. Recent Advances in Subunit Vaccine Carriers. Front Microbiol (2015) 6: doi: 10.3389/fmicb.2014.002012

54. Naghipour Erami A, Rasooli I, Jahangiri A, Darvish Alipour Astarh A. Anti-Omp34 Antibodies Protect Against Acinetobacter baumannii in a Murine Sepsis Model. Microb Pathogenesis (2021) 161( Pt B):105291. doi: 10.1016/j.micpath.2021.105291

55. Ansari H, Doosti A, Kargar M, Bijanzadeh M, Jaafarinia M. Cloning of the Immunogenicity of Outer Membrane Protein A (ompA) Gene from Acinetobacter baumannii into the Eukaryotic Expression Vector pBacE4.1 as DNA Vaccine. Indian J Microbiol (2018) 58(2):741-7. doi: 10.1007/s12028-017-6705-x

56. Ansari H, Tahmasbei-Birgani M, Bijanzadeh M, Doost A, Kargar M. Study of the Immunogenicity of Outer Membrane Protein A (ompA) Gene from Acinetobacter baumannii as DNA Vaccine Candidate in vivo. Iran J Basic Med Sci (2019) 22(6):669-75. doi: 10.22038/ijbis.2019.30799.7427

57. Hashemzehi R, Doost A, Kargar M, Jaafarinia M. Cloning and Expression of nlpA Gene as DNA Vaccine Candidate Against Acinetobacter baumannii. Mol Biol Rep (2018) 45(4):395-401. doi: 10.1007/s10077-018-4167-9

58. van Gils MJ, van Willigen HDG, Wynberg E, Han AX, van der Straten K, Burger JA, et al. A Single mRNA Vaccine Dose in COVID-19 Patients Boosts Neutralizing Antibodies Against SARS-CoV-2 and Variants of Concern. Cell Rep Med (2022) 3(1):100486. doi: 10.1016/j.xcrm.2021.100486

59. Bahey-El-Din M, Mohamed SA, Sheweta SA, Haroun M, Zaghboul TI. Recombinant N-Terminal Outer Membrane Porin (OmpR) of Pseudomonas Aeruginosa is a Promising Vaccine Candidate Against Both P. Aeruginosa and Some Strains of Acinetobacter baumannii. Int J Med Microbiol JMM (2020) 315(1):151415. doi: 10.1016/j.ijmm.2020.05.013

60. Vieira de Araujo AE, Conde LV, da Silva Junior HC, de Almeida Machado L, Lara FA, Chapeaurouge A, et al. Cross-Reactivity and Immunotherapeutic Potential of BmA Recombinant Protein From Acinetobacter baumannii. Microbes Infect (2021) 23(4-5):104801. doi: 10.1016/j.micinf.2021.104801

61. Borry P, Bentzen HB, Budin-Ljosec I, Cornel MC, Howard HC, Feeney O, et al. The Challenges of the Expanded Availability of Genomic Information: An Agenda-Setting Paper. J Commun Genet (2018) 9(2):103–16. doi: 10.1016/s12687-017-0331-7

62. Lahiri C, Pawar S, Sabarinathan R, Ashraf MI, Chand Y, Chakravortty D. Interactome Analyses of Salmonella Pathogenicity Islands Reveal SicA Indispensable for Virulence. J Theor Biol (2014) 363:188–97. doi: 10.1016/j.jtbi.2014.08.013

63. Phillips KA, Douglas MP, Marshall DA. Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA (2020) 324(20):2029. doi: 10.1001/jama.2020.19933

64. Zadeh Hosseingholi E, Zarrini G, Pashazadeh M, Gheibi Hayat SM, Molavi G. In Silico Identification of Probable Drug and Vaccine Candidates Against Antibiotic-Resistant Acinetobacter baumannii. Microb Drug Resist (Larchmont NY) (2021) 26(5):456–67. doi: 10.1089/mdr.2019.0236

65. Solanki V, Tiwari V. Subtractive Proteomics to Identify Novel Drug Targets and Reverse Vaccinology for the Development of Chimeric Vaccine Against Acinetobacter baumannii. Sci Rep (2018) 8(1):9044. doi: 10.1038/s41598-019-26689-7

66. Tettelin H, Massignani V, Cieslewicz MJ, Donati C, Medini D, Ward NL, et al. Genome Analysis of Multiple Pathogenic Isolates of Streptococcus Galactiae: Implications for the Microbial “Pan-Genome”. Proc Natl Acad Sci (2005) 102(39):19350–5. doi: 10.1073/pnas.0506758102

67. Vivona S, Gurdy JL, Ramachandran S, Brinkman FSL, Raghava GPS, Flower DJ, et al. Computer-Aided Biotechnology: From Immuno-Informatics to Reverse Vaccinology. Trends Biotechnol (2008) 26(4):190–200. doi: 10.1016/j.tibtech.2007.12.006

68. Mishra R, Tan YC, El-Aal AAAA, Lahiri C. Computational Identification of the Plausible Molecular Vaccine Candidates of Multidrug-Resistant Salmonella Enterica. In: A Lamas, P Regal and CM Franco (Eds.), Salmonella Spp. - A Global Challenge. IntechOpen (2021). doi: 10.5772/intechopen.95856

69. Pasala C, Chilamakuri CSR, Katari SK, Nahalom RM, Bitla AR, Umamaheswari A. An in Silico Study: Novel Targets for Potential Drug and Vaccine Design Against Drug Resistant P. Aeruginosa. J Theor Biol (2020) 506:10. doi: 10.1016/j.jtbi.2020.104114

70. Beiranvand S, Doosti A, Mirzaei SA. Putative Novel B-Cell Vaccine Candidates Against Acinetobacter baumannii Using the Reverse Vaccinology Method. Microb Pathog (2020) 143:104114. doi: 10.1016/j.micpath.2020.104114

71. Bagos PG, Liakopoulos TD, Spyropoulos IC, Hamodrakas SJ. PRED-TMBB: A Web Server for Predicting the Topology of -Barrel Outer Membrane Proteins. Nucleic Acids Res (2004) 32(Web Server):W400–4. doi: 10.1093/nar/gkh417

72. Beiravan S, Doost A, Mirzaei SA. Putative Novel B-Cell Vaccine Candidates Identified by Reverse Vaccinology and Genomics Approaches to Control Acinetobacter baumannii Serotypes. Infect Genet Evol J Mol Epidemiol Evolution Genet Infect Dis (2021) 96:105138. doi: 10.1016/j.meegid.2021.105138

73. Smline Giria AS. Delineating the Immuno-Dominant Antigenic Vaccine Peptides Against gacS-Sensor Kinase in Acinetobacter baumannii: An in Silico Investigational Approach. Front Microbiol (2020) 11:2078. doi: 10.3389/fmicb.2020.02078

74. Novovic K, Mihajlovic S, Dinic M, Malesevic M, Miljkovic M, Kojic M, et al. Acinetobacter Spp. Porin Omp33-36: Classification and Transcriptional Response to Carbapenems and Host Cells. PloS One (2018) 13(8): e0201608. doi: 10.1371/journal.pone.0201608
84. Sogasu D, Girija ASS, Gunasekaran S, Priyadarsini JV. Molecular Characterisation and Epitope-Based Vaccine Predictions for ompA Gene Associated With Biofilm Formation in Multidrug-Resistant Strains of A. baumannii. In Silico Pharmacol (2021) 9(1):15. doi: 10.1007/s40203-020-00074-7

85. McConnell MJ, Martin-Galiano AJ. Designing Multi-Antigen Vaccines Against Acinetobacter baumannii Using Systematic Approaches. Frontiers in Immunology. (2021) 12:1223. doi: 10.3389/fimmu.2021.666742

86. Touhidinia M, Sefid F, Bidakhdavii M. Design of a Multi-Epitope Vaccine Against Acinetobacter baumannii Using Immunoinformatics Approach. Int J Pept Res Ther (2021) 27(4):2417–37. doi: 10.1007/s10999-021-10262-4

87. Khalid K, Irum S, Ullah SR, Andleeb S. Immunoepitope Prediction of Novel Vaccine Candidate Against Infections Caused by Acinetobacter baumannii. Int J Pept Res Ther (2022) 28(3):16. doi: 10.1007/s10999-021-10316-7

88. Shahid F, Zaheer T, Ashraf ST, Shehroz M, Anwer F, Naz A, et al. Chimeric Multi-Epitope Assembly Peptide Vaccine Against Acinetobacter baumannii Immunised Mice. Iranian J Allergy Asthma Immunol (2020) 16:1819–36. doi: 10.2147/IJA.S96527

89. Song X, Zhang H, Zhang D, Xie W, Zhao G. Bioinformatics Analysis and Immunogenic Fimbrial Protein. Infect Genet Evol: J Mol Epidemiol Infect Dis (2015) 13:13213. doi: 10.1016/j.meegid.2018.04.019

90. Ahmad S, Sanaghan KE, Azam SS. Combating Tigiouscycine Resistant Acinetobacter baumannii: A Leap Forward Towards Multi-Epitope Based Vaccine Discovery. Eur J Pharm Sci. Off J Eur Fed Pharm Sci (2019) 132:1–17. doi: 10.1016/j.ejps.2019.02.023

91. Mehdinejadiani K, Hashemi A, Bandehpour M, Rahmani H, Ranjbar MM, Shahid F, et al. Novel Vaccine Candidate Against Infections Caused by Acinetobacter baumannii. J Mol Graph Model (2018) 83:1–11. doi: 10.1016/j.jmgm.2018.04.020

92. Yao C, Zhang H, Zhang D, Xie W, Zhao G. Bioinformatics Analysis and Epitope Screening of a Potential Vaccine Antigen TolB From Acinetobacter baumannii Outer Membrane Protein. Infect Genet Evol: J Mol Epidemiol Infect Dis (2018) 62:673–9. doi: 10.1016/j.meegid.2018.04.019

93. Ahmad S, Azam SS. A Novel Approach of Virulome Based Reverse Vaccinology for Exploring and Validating Peptide-Based Vaccine Candidates Against the Most Troublesome Nosocomial Pathogen: Acinetobacter baumannii. J Mol Graph Model (2018) 83:1–11. doi: 10.1016/j.jmgm.2018.04.020

94. Song X, Zhang H, Zhang D, Xie W, Zhao G. Bioinformatics Analysis and Epitope Screening of a Potential Vaccine Antigen TolB From Acinetobacter baumannii Outer Membrane Protein. Infect Genet Evol: J Mol Epidemiol Infect Dis (2018) 62:673–9. doi: 10.1016/j.meegid.2018.04.019

95. Song X, Zhang H, Zhang D, Xie W, Zhao G. Bioinformatics Analysis and Epitope Screening of a Potential Vaccine Antigen TolB From Acinetobacter baumannii Outer Membrane Protein. Infect Genet Evol: J Mol Epidemiol Infect Dis (2018) 62:673–9. doi: 10.1016/j.meegid.2018.04.019

96. Ahmad S, Managhan KE, Azam SS. Combating Tigiouscycine Resistant Acinetobacter baumannii: A Leap Forward Towards Multi-Epitope Based Vaccine Discovery. Eur J Pharm Sci. Off J Eur Fed Pharm Sci (2019) 132:1–17. doi: 10.1016/j.ejps.2019.02.023

97. Khalid K, Irum S, Ullah SR, Andleeb S. Immunoepitope Prediction of Novel Vaccine Candidate Against Infections Caused by Acinetobacter baumannii. Int J Pept Res Ther (2022) 28(3):16. doi: 10.1007/s10999-021-10316-7

98. Shahid F, Zaheer T, Ashraf ST, Shehroz M, Anwer F, Naz A, et al. Chimeric Vaccine Designs Against Acinetobacter baumannii Using Pan Genome and Reverse Vaccinology Approaches. Sci Rep (2021) 11(1):13213. doi: 10.1038/s41598-021-92501-8

99. Ahmad S, Ranaghan KE, Azam SS. Combating Tigiouscycine Resistant Acinetobacter baumannii: A Leap Forward Towards Multi-Epitope Based Vaccine Discovery. Eur J Pharm Sci. Off J Eur Fed Pharm Sci (2019) 132:1–17. doi: 10.1016/j.ejps.2019.02.023

100. Sogasu D, Girija ASS, Gunasekaran S, Priyadarsini JV. Molecular Characterisation and Epitope-Based Vaccine Predictions for ompA Gene Associated With Biofilm Formation in Multidrug-Resistant Strains of A. baumannii. In Silico Pharmacol (2021) 9(1):15. doi: 10.1007/s40203-020-00074-7

101. Tan and Lahiri Vaccine Candidates of Acinetobacter baumannii
